

DR. Magdi Hanna MD

Consultant In Pain Medicine

Director - Analgesics and Pain Research Unit (APRU), UK

Magdi Hanna was appointed a Consultant and H Senior Lecturer in Pain Medicine at the *Department of Anesthesia, Intensive Care and Pain Relief at King's College University Hospital, London in 1984.*

He became the Director of the Pain Research Unit (PRU) at King's College School of Medicine in London (UK) in 1985. The PRU carried extensive research in the mechanisms of acute and chronic pain as well as pharmacodynamic and pharmacokinetics of old and novel compounds used and planned for the management of pain.

In 2003- 2008, Dr Hanna was appointed clinical director The PCRH (Pain Clinical Research Hub), a collaborative academic research unit at King's College School of Medicine and Pfizer, which specializes in developing pain biomarkers for chronic, nociceptive and neuropathic pain states.

He is a member of the European Academy of Anesthesiology, European Association for Palliative Care (EAPC), International Association of the Study of Pain (IASP) and the British Pain Society for the last 25 years.

Currently, an independent Consultant in Pain Medicine at the BMI Healthcare hospitals and the Clinical Director of the Analgesics & Pain Research Unit which specializes in coordinating phase 1b to phase 4 drug development programs and acts as an independent advisory unit for the pharmaceutical industry and academic research units.

He is the co-director on the Faculty of the EFIC Pain school for "Neuropathic Pain" in Italy since 2010.

Dr Hanna has been awarded the "Freedom of the City of London" in 2015.

He has published extensively on the subject of pain in peer-reviewed journals as well as editing two books on pain; the most recent "Cancer Pain" has won high commendation award in the BMA awards for medical books.

Some selective PUBLICATIONS

Books:

- Cancer Pain: edited by **Magdi Hanna** & B Zylic, published by Springer 2014
Successful Management of Chronic Non Cancer Pain; edited by **Magdi Hanna**,
Published by Evolving Medicine Ltd 2011.
- Tramadol/Dexketoprofen Analgesic Efficacy Compared with Tramadol/Paracetamol in Moderate to Severe Postoperative Acute Pain: Subgroup Analysis of a Randomised, Double-Blind, Parallel Group Trial - DAVID Study, **Magdi Hanna**, Antonio Montero, Serge Perrot, Giustino Varrassi
Pain Ther. 2021 Feb 11. doi: 10.1007/s40122-020-00228-7.
- Tramadol/Dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study).
Gay-Escoda C, **Hanna M**, Montero A, Dietrich T, Milleri S, Giergiel E, Zoltán TB, Varrassi G.
BMJ Open. 2019 Feb 19;9(2):e023715.
- A review of dexketoprofen trometamol in acute pain.
Hanna M, Moon JY.
Curr Med Res Opin. 2019 Feb;35(2):189-202. doi: 10.1080/03007995.2018.1
- Multimodal analgesia in moderate to severe pain: a role for a new fixed combination of dexketoprofen and tramadol.
Varrassi G¹, **Hanna M**², Macheras G³, Montero A⁴, Montes Perez A, Meissner W⁶
Perrot S⁷, Scarpignato C
Curr Med Res Opin. 2017 Mar 22:1-19.